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A B S T R A C T
The Millennium Development Goal 5, a project signed in 2000, intended to improve maternal health and reduce
maternal mortality by 75% by 2015. Despite all eﬀorts, little progress has been achieved in low and middle-
income countries (LMIC) and 99% of all maternal deaths related to pre-eclampsia (PE) still occur in these set-
tings. It is important to determine whether women in LMIC, where PE carries a greater risk than in high-income
countries (HIC), have unique risk factors. Some variances may alter the risk, severity and pertinent pathophy-
siology of PE. We posit based upon this, that women from LMIC may have biomarkers speciﬁc to this population.
Discovering such speciﬁc biomarkers and testing the relevance of biomarkers developed in high-income popu-
lations could increase the clinical usefulness of these analyses without increasing cost-eﬀective approaches for
prediction of PE.
Here we brieﬂy describe our platform to develop the PREPARE – Biobank in tertiary hospitals or basic units
for antenatal care from 6 diﬀerent cities in Brazil.
The PREPARE – Biobank has been developed with two arms. The ﬁrst arm is a cross-sectional study that will
collect clinical information and biosamples from more than 1000 women who developed preterm PE. The second
arm is a cohort study of 7000 women. It will collect clinical information and longitudinal biosamples from
women at three times during pregnancy,< 16weeks, between 28 and 32 weeks and at delivery or diagnosis of
adverse outcomes.
The biobank will be supported and complemented by a Brazilian database using the CoLab COLLECT
Database.
1. Introduction
Data from the World Health Organization (WHO) show that every
day, 830 women die from preventable causes related to pregnancy and
childbirth, with the vast majority of these deaths (99%) occurring in
low and middle-income countries. In addition, among the 133 million
babies born alive each year, 2.8 million die in the ﬁrst week of life. The
patterns of these deaths are similar to the patterns for maternal deaths,
the majority occurring in developing countries [1].
This sad reality motivated the creation of the Millennium
Development Goal 5 (MDG 5), a project signed in 2000 to improve
maternal health and reduce maternal mortality by 75% by 2015.
Despite all eﬀorts, little progress has been achieved in developing
countries. In Brazil for example, the oﬃcial report on maternal mor-
tality ratio in 1999 was 73. In 2015 this ratio was 58 [2,3].
Low and middle-income (LMIC) countries still suﬀer with pre-
eclampsia (PE), post-partum hemorrhage and illegal abortions as im-
portant causes of maternal deaths. In Latin America, including Brazil,
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hypertensive disorders, mainly PE, account for 26% of all causes of
maternal deaths [4].
It is clear that LMICs beneﬁt from assistance from high resource
centres to improve the management of PE. This has begun in Africa and
India, with encouraging results [5]. Therefore, our aim is to extend this
approach to Brazil and Latin America. We believe that in addition to the
usual strategy of implementing approaches that have been successful in
high-income countries (HIC), eﬀective management of PE and other
adverse pregnancy outcomes in Brazil demands an understanding of the
pathophysiology of the disease in Brazil. To enable rational antenatal
risk assessment, prophylaxis and treatment, we believe we must con-
sider potentially unique features of the disorder in the local setting.
Currently, risk assessment of PE, using demographic and clinical fea-
tures and biomarkers, has evolved almost exclusively in HIC. This ap-
proach has two problems in terms of usefulness for LMIC. Firstly, dis-
coveries developed in high-income populations may not be completely
pertinent to other populations. For example while some authors de-
monstrated 90% sensitivity for prediction of PE using a set of bio-
markers in Europe (PAPP-A, PlGF, PP-13 and Doppler of uterine ar-
teries), Oliveira et al. showed only 52% in United States of America
[6,7]. Secondly, platforms developed for HIC maybe too expensive to be
useful in LMIC.
Bearing these considerations in mind, it is important to determine
whether women in LMIC, where PE carries a greater risk than in HIC,
have unique risk factors. Some variances (e.g. diet, smoking status,
coital and partnership history) may alter the risk, severity and pertinent
pathophysiology of PE compared to HIC. We posit based upon this, that
women from LMIC may have biomarkers speciﬁc to this population.
Discovering such speciﬁc biomarkers and testing the relevance of bio-
markers developed in high-income populations could increase the
clinical usefulness of these analyses without increasing cost-eﬀective
approaches for prediction of PE for this population.
The Global Pregnancy Collaboration (CoLab), a group of interna-
tional researchers from more than 40 countries believes that the crea-
tion of a robust biobank linked to a reliable databank is one of the most
powerful initiatives, to rapidly and economically, achieve the goal of
understanding potential unique features of diseases in the local popu-
lation. This will thus empower LMICs to achieve the goal of MDG 5.
Here we describe our platform to develop the PREPARE – Biobank in
Brazil. The PREPARE – (Prematurity REduction by Preeclampsia cARE
project) is an audacious project that has been developed either in ter-
tiary hospitals or basic units for antenatal care from 6 diﬀerent cities in
Brazil. It has been supported by an association between Bill & Melinda
Gates Foundation and CNPq (Brazilian Government).
The PREPARE – Biobank has been developed with two arms. The
ﬁrst arm is a cross-sectional study that will collect clinical information
and biosamples from 1000 women who developed preterm PE. The
second arm is a cohort study of 7000 women. It will collect clinical
information and longitudinal biosamples from women at three times
during pregnancy,< 16weeks, between 28 and 32weeks and at de-
livery or diagnosis of adverse outcomes. The population to be included
in the PREPARE is comprised mainly of low-income women. The
PREPARE – Biobank will provide a unique opportunity to bank biolo-
gical materials from Brazilian women, diﬀerent from HIC, for present
and future mechanistic studies.
2. Purpose of the PREPARE database and biobank
Our purpose is to evaluate women with PE and other adverse
pregnancy outcomes using data and materials from this PREPARE da-
tabase and biobank, searching for unique biological biomarkers and
testing biomarkers developed in HIC in the Brazilian population. We
believe this will provide insights that may also be pertinent to other
LMICs.
3. The PREPARE – database
The biobank will be supported and complemented by Brazilian
database using the CoLab COLLECT Database (Myatt L, Roberts JM,
Redman CWG, Global Pregnancy C. Availability of COLLECT), a data-
base for pregnancy and placental research studies worldwide [8]. This
is a very complete database with many deﬁned risk factors for PE and
additional information. All data has been recorded and stored in a se-
cure on-line system provided by MedSciNet group. Details including the
mother’s own birth-weight and mode of delivery, her length of coha-
bitation with the father of her child, and many others will be recorded.
We expect to collect this high quality demographic, clinical and out-
come data for 7000 women from the cohort arm and for more than
1500 women from the cross-sectional arm. A pilot questionnaire about
air pollution and PE will be introduced among women recruited with
preterm PE in one of the centres involved in the study. The implication
of air pollution in the pathophysiology of PE is a recent topic that needs
to be addressed.
4. The PREPARE – biobank
All women at the cohort arm will provide blood (plasma and
serum), urine and DNA samples at≤16 and 28–32weeks’ gestation and
at the time of delivery or adverse outcomes. This model will allow us to
study other adverse outcomes including preterm birth, small for ge-
stational age and others.
Standardized operating procedures (SOPs), approved by the
Management Team, was designed to guide recruitment, clinical proce-
dures, and sample collection, processing and storage.
We are providing each antenatal care unit with a tabletop centrifuge
and a small −20 °C freezer. Each tertiary centre will have a larger
−20 °C freezer and the Biorepository will have seven −80 °C freezers.
Serum and plasma will be prepared and aliquoted at the antenatal
centre and stored temporarily in small−20 °C freezers with transfer to
the associated centre weekly. At the centre, samples will be bar coded,
entered into the inventory system and stored at−20 °C. Samples will be
transferred monthly on dry ice for long-term storage (−80 °C) at the
Study Centre Laboratory. The inventory system information will in-
clude the duration of time from draw to processing, entry to −20 °C
freezer and time in −20 °C freezer prior to entry to −80 °C freezer.
Facilities for long-term sample storage (Biorepository) will be lo-
cated at the Study Centre Laboratory, Botucatu São Paulo State
University, where seven −80 °C freezers with a nitrogen back-up
system purchased for this purpose will be installed in the Laboratory
with emergency power and alarms. In the event of freezer malfunction
back-up freezers are available at this site for use during freezer repair.
We have selected a dispersed system of accrual and temporary storage
and centralized long-term storage as the safest and most economical.
Maintaining samples at−20 °C is in many settings considered suﬃcient
for long-term storage. Our experience is that long-term (months to
years) is more eﬀective at−80 °C but for short-term (weeks)−20 °C is
adequate. The availability of the alarm emergency power and back-up
capabilities will provide adequate protection. We envision this as the
inception of the Biorepository, which we will extend with future
funding.
Through CoLab this data and biological materials will be made ac-
cessible to the pregnancy research community. This includes LMIC-
based investigators who will have access to this rich data set and
Biobank for studies that would, at this time, be beyond their practical
ability to conduct due to local resource constraints. Through HIC cen-
tres in CoLab we will have samples to compare ﬁndings in women in
Brazil and HIC centres.
We will also work with existing Bill & Melinda Gates Foundation
centres and other agencies striving to harmonize data and sample col-
lection in LMICs. The intent is to acquire useful data and samples ap-
propriate for assessment of PE and other pregnancy outcomes. The
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approach will balance robust data and biomaterials collection with
what is achievable in LMICs.
We believe the combined approach of testing the value of estab-
lished approaches and searching for unique biomarkers and patho-
physiological features in the local settings using biobanks and data-
banks in LMIC will help to achieve the goals of MDG 5. CoLab oﬀers
assistance to LMICs for applications to obtain funding for this goal
(https://pregnancycolab.tghn.org) and also will provide the COLLECT
database for these eﬀorts (https://pregnancycolab.tghn.org/articles/
collect-database/).
This work has been approved by the National Central Ethical
Committee on research involving Human Subjects (CAAE:
53092916.4.2008.5411) and by each Local Ethical Committee of the
participating centres.
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